Biocon Limited — Updates, 03-08-2026: General Updates

Biocon launched Yesafili™ (biosimilar Aflibercept) in the U.S., an FDA-approved interchangeable biosimilar to Eylea® 2 mg. This expands Biocon's ophthalmology presence in a ~$5.89 billion market, offering a key treatment for eye conditions like age-related macular degeneration.